130 related articles for article (PubMed ID: 3258792)
1. Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.
Bjorn MJ; Smith HS; Dairkee SH
Cancer Immunol Immunother; 1988; 26(2):121-4. PubMed ID: 3258792
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
3. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
4. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
[TBL] [Abstract][Full Text] [Related]
6. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
7. Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin.
Fulcher S; Foulks GN; Wilkerson M; Cobo LM; Houston LL; Hatchell D
Cornea; 1993 Sep; 12(5):391-6. PubMed ID: 8306659
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid disrupts the Golgi apparatus and increases the cytosolic routing of specific protein toxins.
Wu YN; Gadina M; Tao-Cheng JH; Youle RJ
J Cell Biol; 1994 May; 125(4):743-53. PubMed ID: 8188744
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
10. The synovial membrane, liver, and tongue: target organs for a ricin A-chain immunotoxin (ZD0490).
Westwood FR; Jones DV; Aldridge A
Toxicol Pathol; 1996; 24(4):477-83. PubMed ID: 8864189
[TBL] [Abstract][Full Text] [Related]
11. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
[TBL] [Abstract][Full Text] [Related]
12. The conjugation of an AQP1-directed immunotoxin in the study of site-directed therapy within the CNS.
Surash S; Nemeth P; Chakrabarty A; Chumas P
Childs Nerv Syst; 2011 May; 27(5):811-8. PubMed ID: 21104258
[TBL] [Abstract][Full Text] [Related]
13. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
14. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the activity of immunotoxins by analogues of verapamil.
Pirker R; FitzGerald DJ; Raschack M; Frank Z; Willingham MC; Pastan I
Cancer Res; 1989 Sep; 49(17):4791-5. PubMed ID: 2788030
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
Weiner LM; O'Dwyer J; Kitson J; Comis RL; Frankel AE; Bauer RJ; Konrad MS; Groves ES
Cancer Res; 1989 Jul; 49(14):4062-7. PubMed ID: 2786751
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
[TBL] [Abstract][Full Text] [Related]
18. Refinement of an indirect immunotoxin assay of monoclonal antibodies recognising the human small cell lung cancer cluster 2 antigen.
Derbyshire EJ; de Leij L; Wawrzynczak EJ
Br J Cancer; 1993 Jun; 67(6):1242-7. PubMed ID: 8390281
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
[TBL] [Abstract][Full Text] [Related]
20. [Selective cytotoxic effect of an immunotoxin on human erythroid tumor cells].
Tonevitskiĭ AG; Agapov II; Mechetner EB
Mol Biol (Mosk); 1991; 25(5):1181-7. PubMed ID: 1753950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
